Health Insurance - Genetic Testing and Cancer Imaging - Required Coverage and Prohibited Cost-Sharing
Summary
SB476 would require certain Maryland health insurers, nonprofit health service plans, and health maintenance organizations to cover genetic testing for individuals with a personal or family history of cancer when the test is recommended by a health care professional and aligns with evidence-based clinical practice guidelines. If that testing shows an increased cancer risk, the bill also requires coverage for follow-up evidence-based cancer imaging recommended for the identified cancer type and based on the most recent National Comprehensive Cancer Network guidelines.
The bill further prohibits copayments, coinsurance, and deductibles for the required genetic testing and follow-up imaging, with limited exceptions for health savings account-qualified high deductible health plans to preserve federal tax treatment. The mandate would apply to policies, contracts, and health benefit plans issued, delivered, or renewed in Maryland on or after January 1, 2026.
Impact
SB476 would amend the Insurance Article by adding a new Section 15-861, creating a new coverage mandate for specified carriers and HMOs in Maryland. It expands required health benefits to include genetic testing for cancer-risk assessment and subsequent cancer imaging, while also restricting cost-sharing for those services. The bill would affect insurers, nonprofit health service plans, HMOs, and policyholders enrolled in affected health plans, and it is designed to take effect for plans issued, delivered, or renewed on or after January 1, 2026.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the measure appears to be framed as a patient-access and preventive-care bill rather than a controversial restructuring of coverage. Its emphasis on evidence-based guidelines, cancer risk detection, and eliminating out-of-pocket costs suggests a generally supportive policy rationale aimed at improving early diagnosis and reducing financial barriers. No formal vote history or hearing record is available here to indicate opposition or support from legislators or stakeholders.
Contention
The main policy tension is likely to be between expanded access to cancer-related genetic testing and imaging versus the added cost burden on insurers and health plans. Another point of potential contention is the prohibition on cost-sharing, which may raise premium or utilization concerns, though the bill narrows coverage to testing and imaging that are medically recommended and guideline-based. The high-deductible health plan carveout also reflects a technical concern about preserving federal health savings account eligibility, indicating attention to federal tax-law compliance.